12.5 mg semaglutide OL 12.5mg 2.5mg/ml x 5ml Semaglutide 5mg/5 Vials, $68.25/Vial, 99%

3 Pharmacology GLP-1 is one of several gastric incretin hormones released in response to oral glucose intake

Semaglutide mimics GLP-1 and triggers 4 key actions: Curbs your appetite : Semaglutide tells the appetite center in your brain that youre full, suppressing your appetite Insulin release : Signals the pancreas to produce insulin for blood sugar control Suppresses glucagon release: Glucagon is a hormone released by the pancreas and raises blood glucose levels

CagriSema , Novo Nordisks co-formulation of semaglutide 2.4mg and the long-acting amylin analogue cagrilintide, demonstrated 22.7% body weight reduction in the REDEFINE-1 Phase 3 trial substantially exceeding standalone semaglutide and positioning Novo Nordisk to defend GLP-1 market leadership against tirzepatides superior weight loss profile

This is a strategic way to use supplementation to support long-term joint health

This dual benefit makes it an attractive option for individuals with both obesity and cardiovascular risk factors